SeaStar Medical (NASDAQ:ICU – Get Free Report) posted its earnings results on Wednesday. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.08), Zacks reports. SeaStar Medical had a negative net margin of 795.51% and a negative return on equity of 162.75%.
SeaStar Medical Price Performance
Shares of NASDAQ:ICU traded up $0.02 during mid-day trading on Wednesday, reaching $1.92. 140,335 shares of the company were exchanged, compared to its average volume of 130,569. SeaStar Medical has a 1 year low of $1.84 and a 1 year high of $5.38. The firm’s 50-day simple moving average is $3.03 and its 200 day simple moving average is $3.29. The firm has a market cap of $10.21 million, a price-to-earnings ratio of -0.49 and a beta of -1.07.
Wall Street Analyst Weigh In
A number of equities analysts have recently weighed in on ICU shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of SeaStar Medical in a report on Thursday, October 15th. Wall Street Zen upgraded shares of SeaStar Medical from a “sell” rating to a “hold” rating in a report on Saturday, September 19th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, SeaStar Medical has a consensus rating of “Hold” and a consensus target price of $8.00.
Check Out Our Latest Stock Analysis on ICU
SeaStar Medical Company Profile
SeaStar Medical Holding Corporation (NASDAQ: ICU) is a medical technology company developing therapies designed to address hyperinflammation, an excessive immune response that can contribute to organ damage in critically ill patients. The company’s platform is intended to selectively target and modulate pro-inflammatory immune cells while preserving the body’s broader immune function. Its lead product is the Selective Cytopheretic Device (SCD), an extracorporeal blood-purification device used alongside continuous kidney replacement therapy.
Further Reading
- Five stocks we like better than SeaStar Medical
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for SeaStar Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaStar Medical and related companies with MarketBeat.com's FREE daily email newsletter.
